Global Plasma Protein Therapeutics Market Growth 2025-2031

The global Plasma Protein Therapeutics market size is predicted to grow from US$ 34560 million in 2025 to US$ 54490 million in 2031; it is expected to grow at a CAGR of 7.9% from 2025 to 2031.

Plasma Protein Therapeutics is use blood products to treat disease.Human blood plasma is nature's raw material for dozens of life-saving treatments and medications. By extracting the active ingredients and disinfection, people get related preparations from blood plasma, which is called blood product.

The plasma protein therapeutics market is driven by the increasing prevalence of rare and chronic diseases such as hemophilia, primary immunodeficiency, and autoimmune disorders, which require life-saving plasma-derived treatments. Advances in plasma fractionation techniques and the growing demand for immunoglobulins, albumin, and clotting factors are further fueling market growth. Additionally, improvements in diagnostic technologies have led to earlier detection and treatment of these conditions, expanding the patient pool for plasma protein therapies. Increasing awareness and access to these treatments in developing regions are also contributing to market expansion.A significant challenge in the plasma protein therapeutics market is the limited availability of plasma due to the complex and time-consuming process of plasma collection and fractionation. This often results in supply shortages, which can affect patient access to essential therapies. The high cost of plasma protein therapies, due to the labor-intensive production process and stringent regulatory requirements, also poses a barrier to treatment affordability. Furthermore, the market faces increasing competition from recombinant therapies, which are being developed as alternatives to plasma-derived products, potentially impacting market share.

Takeda, CSL and Grifolsare the leaders of the Plasma Protein Therapeutics industry, The top five manufacturers held 73.28% of the market. North America is the major region of the global market, which takes about 40% market share.

LP Information, Inc. (LPI) ' newest research report, the “Plasma Protein Therapeutics Industry Forecast” looks at past sales and reviews total world Plasma Protein Therapeutics sales in 2024, providing a comprehensive analysis by region and market sector of projected Plasma Protein Therapeutics sales for 2025 through 2031. With Plasma Protein Therapeutics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Plasma Protein Therapeutics industry.

This Insight Report provides a comprehensive analysis of the global Plasma Protein Therapeutics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Plasma Protein Therapeutics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Plasma Protein Therapeutics market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Plasma Protein Therapeutics and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Plasma Protein Therapeutics.

This report presents a comprehensive overview, market shares, and growth opportunities of Plasma Protein Therapeutics market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:
Coagulation Factor
Immune Globulin
Albumin
Others

Segmentation by Application:
Hemophilia
PID
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Takeda
CSL
Grifols
Octapharma
Kedrion
LFB Group
Biotest
BPL
RAAS
CBPO
Hualan Bio
Tiantan Bio
Shuanglin Bio
Boya Bio
Yuanda Shuyang
Weiguang Bio
Nanyue Bio
KM Biologics

Key Questions Addressed in this Report

What is the 10-year outlook for the global Plasma Protein Therapeutics market?

What factors are driving Plasma Protein Therapeutics market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Plasma Protein Therapeutics market opportunities vary by end market size?

How does Plasma Protein Therapeutics break out by Type, by Application?

Please note: The report will take approximately 2 business days to prepare and deliver.